Ubs Asset Management Americas Inc Recursion Pharmaceuticals, Inc. Transaction History
Ubs Asset Management Americas Inc
- $446 Billion
- Q3 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 4,196,978 shares of RXRX stock, worth $17.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,196,978
Previous 4,615,516
9.07%
Holding current value
$17.4 Million
Previous $23.4 Million
12.3%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding RXRX
# of Institutions
361Shares Held
301MCall Options Held
7.71MPut Options Held
4.85M-
Vanguard Group Inc Valley Forge, PA39.8MShares$165 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl33.5MShares$139 Million1.15% of portfolio
-
Baillie Gifford & CO24MShares$99.3 Million0.09% of portfolio
-
State Street Corp Boston, MA18.3MShares$75.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$71.7 Million0.0% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $747M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...